Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2013, 14(5), 9338-9364; doi:10.3390/ijms14059338
Review

Biomarkers for Anti-Angiogenic Therapy in Cancer

1
, 2
, 3,4
, 1
 and 3,*
Received: 28 February 2013; in revised form: 25 March 2013 / Accepted: 18 April 2013 / Published: 29 April 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [557 KB, uploaded 19 June 2014]
Abstract: Angiogenesis, the development of new vessels from existing vasculature, plays a central role in tumor growth, survival, and progression. On the molecular level it is controlled by a number of pro- and anti-angiogenic cytokines, among which the vascular endothelial growth factors (VEGFs), together with their related VEGF-receptors, have an exceptional position. Therefore, the blockade of VEGF signaling in order to inhibit angiogenesis was deemed an attractive approach for cancer therapy and drugs interfering with the VEGF-ligands, the VEGF receptors, and the intracellular VEGF-mediated signal transduction were developed. Although promising in pre-clinical trials, VEGF-inhibition proved to be problematic in the clinical context. One major drawback was the generally high variability in patient response to anti-angiogenic drugs and the rapid development of therapy resistance, so that, in total, only moderate effects on progression-free and overall survival were observed. Biomarkers predicting the response to VEGF-inhibition might attenuate this problem and help to further individualize drug and dosage determination. Although up to now no definitive biomarker has been identified for this purpose, several candidates are currently under investigation. This review aims to give an overview of the recent developments in this field, focusing on the most prevalent tumor species.
Keywords: cancer; anti-angiogenic therapy; biomarkers; VEGF cancer; anti-angiogenic therapy; biomarkers; VEGF
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wehland, M.; Bauer, J.; Magnusson, N.E.; Infanger, M.; Grimm, D. Biomarkers for Anti-Angiogenic Therapy in Cancer. Int. J. Mol. Sci. 2013, 14, 9338-9364.

AMA Style

Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for Anti-Angiogenic Therapy in Cancer. International Journal of Molecular Sciences. 2013; 14(5):9338-9364.

Chicago/Turabian Style

Wehland, Markus; Bauer, Johann; Magnusson, Nils E.; Infanger, Manfred; Grimm, Daniela. 2013. "Biomarkers for Anti-Angiogenic Therapy in Cancer." Int. J. Mol. Sci. 14, no. 5: 9338-9364.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert